Imagion Biosystems is now a publicly traded company after completing a heavily supported A$12 million initial public offering (IPO) on the Australian Securities Exchange. Imagion issued 60 million new shares as part of the IPO at A$0.20 per share, valuing the company at A$43 million upon listing.
The company’s shares trade under the symbol IBX on the Australian Securities Exchange. Download the official announcement.
Positive Final Results of Wayne State Collaboration Drives Completion of Phase 2 Study Protocol for IND Submission to FDA in December
December 2, 2025
Positive Final Results of Wayne State Collaboration Drives Completion of Phase 2 Study Protocol for IND Submission to FDA in December Key Highlights: MagSense® HER2